Navigation Links
Confirmation of Bogoch Replikins Influenza Patents by Harvard-CDC and Scripps-Crucell Data
Date:3/20/2009

BOSTON, March 20 /PRNewswire/ -- Replikins, Ltd. announced today that data recently published from Harvard-CDC and Scripps-Crucell in Nature(1) and Science(2) confirms the 2001 discoveries by Dr. Samuel and Elenore Bogoch of peptides in the hemagglutinin unit of influenza, which they named Replikins, which are shared across flu strains, conserved over time, associated with the last three pandemics of 1918, 1957 and 1968, as well as current H5N1 outbreaks, and are the basis of broad spectrum flu vaccines. The Replikins sequences, as specified by the Bogoches, are the subject of granted patents from 2001 and a 2005 monograph(3).

The amino acid contact points between the neutralizing antibody and the virus that the Harvard-CDC and Scripps-Crucell investigators both observed, out of over 500 possible sites, are in the influenza Replikins. The confirming groups' data also verified the Bogoch 2001 findings of conservation of these very Replikins peptides over decades, and the sharing of Replikins between strains of influenza, making general flu vaccines possible for the first time.

The Replikins peptides, associated with rapid replication, are quantitatively trackable and predictive of the intensity, timing, and country of outbreak. The company's FluForecast(R) software has correctly predicted recent H5N1 outbreaks and the countries in which they were going to occur(4).

Replikins, which are quantitatively related to lethality in influenza and other infectious diseases, such as HIV, anthrax, and malaria, as well as cancer, and a range of animal diseases, are the subject of synthetic vaccines in development at the Company.

1. Sui, J. et al. "Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses." Nature Structural and Molecular Biology, published online: Feb. 22, 2009, doi:10.1038-nsmb.1566.

2. Ekeirt, D.C. et al. "Antibody Recognition of a Highly Conserved Influenza Virus Epitope." Science DOI: 10.1126-science.1171491, Science Published online, Feb. 26, 2009.

3. Bogoch S. and Bogoch, E.S. "Replikins, the Chemistry of Rapid Replication. With examples in influenza, HIV, AIDS, SARS, Malaria, and Cancer." Begell House, Inc., New York, Wallingford, U.K. ISBN 1-56700-200-5, 2005.

4. Online (replikins.com): see "Replikins Press," 2006 - 2008. (Press release #12: Indonesia Reports Experiencing Human H5N1 Mortality Increase, as Predicted Last Year by Replikins' FluForecast(R) Quantitative Virus Analysis; June 8, 2007).

REPLIKINS, Ltd., 38 the Fenway, Boston, MA 02215

http://www.replikins.com

Contact: jjosephson@replikins.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Replikins, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cryoablation of Early Invasive Ductal Breast Cancer With MRI Confirmation Shows Promising Clinical Benefits, According to Study Presented at RSNA
2. Confirmation of HGT Business Day - 18th November 2008
3. ProtoKinetix Receives Independent Confirmation of AAGP Anti-Inflammatory Action
4. Confirmation of Strong Growth Over the First Half of 2008
5. Replikins Oral Vaccine Synthesized in 7 Days Protects 91% of Shrimp Against a Lethal Virus
6. Schering-Plough Announces Collaboration With World Health Organization to Provide Access to Pandemic Influenza Vaccine Technology to Developing Countries
7. Fraunhofer USA Center for Molecular Biotechnology Receives Gates Foundation Grant for Avian Influenza Vaccine Development
8. Seasonal Influenza Activity Increasing Across Europe - H3N2 Dominant Strain
9. Rising H9N2 Influenza Replikin Count Has Doubled That of H5N1
10. DaVita Launches Flu Fighter Program in Support of National Influenza Week
11. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... 4, 2016  Bayer today announced that a ... ® (regorafenib) tablets for the treatment of ... its primary endpoint of a statistically significant improvement ... the efficacy and safety of regorafenib in patients ... with sorafenib. The safety and tolerability were generally ...
(Date:5/3/2016)... India , May 3, 2016 /PRNewswire/ ... (DNA Chip (Genomics, Drug Discovery, Gene Expression) ... End user (Academics Institutes, Diagnostics Centers), Fabrication ... published by MarketsandMarkets, the market is expected ... from USD 7.63 Billion in 2015, growing ...
(Date:5/3/2016)... Boston, MA (PRWEB) , ... May 03, 2016 ... ... that facilitates accessibility to unique bioresearch materials from laboratories across the globe, ... While researchers scramble to increase the pace of research toward treatment and prevention ...
(Date:5/3/2016)... ... May 03, 2016 , ... Nashville Fertility Center ... A contingency of reproductive endocrinologists, including Dr. George Hill at Nashville ... to help them build families. , Ovation Fertility is a nationwide network of ...
Breaking Biology Technology:
(Date:3/15/2016)... March 15, 2016 Yissum Research Development ... technology-transfer company of the Hebrew University, announced today the ... sensing technology of various human biological indicators. Neteera Technologies ... million from private investors. ... the detection of electromagnetic emissions from sweat ducts, enables ...
(Date:3/11/2016)... http://www.apimages.com ) - --> http://www.apimages.com ... at AP Images ( http://www.apimages.com ) - Germany ... produce the new refugee identity cards. DERMALOG will be unveiling this ... Hanover next week.   --> ... to produce the new refugee identity cards. DERMALOG will be unveiling ...
(Date:3/10/2016)... BELL, Pa. , March 10, 2016   Unisys ... U.S. Customs and Border Protection (CBP) is testing its ... San Diego to help identify certain ... States . The test, designed to help determine the ... pedestrian environment, began in February and will run until May ...
Breaking Biology News(10 mins):